Product Information
Registration Status: ActiveSIN15239P
Adjupanrix Pandemic Influenza Vaccine (split virion, inactivated, AS03 adjuvanted) is approved to be sold in Singapore with effective from 2017-05-17. It is marketed by GLAXOSMITHKLINE PTE LTD, with the registration number of SIN15239P.
This product contains Inactivated Influenza Virus 3.75mcg haemagglutinin/dose, and Antigen in the form of INJECTION, EMULSION. It is approved for INTRAMUSCULAR use.
This product is manufactured by Glaxo Operations UK Ltd. in BELGIUM, (trading as Glaxo Wellcome Operations) (Antigen: filling) in UNITED KINGDOM, andGlaxoSmithKline Biologicals S.A. (Antigen: filling) in GERMANY.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.